ScoreWhy is Monte Rosa Therapeutics, Inc. ?
1
With a fall in Net Sales of -95.04%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 2 consecutive quarters
- The company has declared negative results in Dec 25 after 7 consecutive negative quarters
- NET SALES(Q) At USD 4.21 MM has Fallen at -95.04%
- PRE-TAX PROFIT(Q) At USD -44.45 MM has Fallen at -193.18%
- NET PROFIT(Q) At USD -44.5 MM has Fallen at -194.92%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 307.80%, its profits have risen by 46.9%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -8.74% over the previous quarter and currently hold 23% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Monte Rosa Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Monte Rosa Therapeutics, Inc.
303.24%
3.76
94.47%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
162.51%
EBIT Growth (5y)
-42.18%
EBIT to Interest (avg)
-82.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.36
Tax Ratio
34.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.45%
ROCE (avg)
0
ROE (avg)
0.56%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.28
EV to EBIT
-15.83
EV to EBITDA
-18.71
EV to Capital Employed
-6.14
EV to Sales
6.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-16.57%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
CASH AND EQV(HY)
Highest at USD 1,043.32 MM
-28What is not working for the Company
NET SALES(Q)
At USD 4.21 MM has Fallen at -95.04%
PRE-TAX PROFIT(Q)
At USD -44.45 MM has Fallen at -193.18%
NET PROFIT(Q)
At USD -44.5 MM has Fallen at -194.92%
OPERATING PROFIT(Q)
Lowest at USD -48 MM
RAW MATERIAL COST(Y)
Grown by 47.4% (YoY
Here's what is working for Monte Rosa Therapeutics, Inc.
Cash and Eqv
Highest at USD 1,043.32 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Monte Rosa Therapeutics, Inc.
Net Sales
At USD 4.21 MM has Fallen at -95.04%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -44.45 MM has Fallen at -193.18%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -44.5 MM has Fallen at -194.92%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Profit
Lowest at USD -48 MM and Fallen
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite negative
Operating Profit (USD MM)
Raw Material Cost
Grown by 47.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
